Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141563 | 0.94 | PDPK1 (0.63) | PDPK1POLBKMT2AMEN1MAPT | |
| SCHEMBL656058 | 0.93 | PDPK1 (0.62) | PDPK1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL2141566 | 0.88 | PDPK1 (0.78) | PDPK1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL657707 | 0.88 | PDPK1 (0.56) | PDPK1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL657479 | 0.86 | PDPK1 (0.56) | PDPK1POLBKMT2AMEN1MAPT | |
| SCHEMBL657492 | 0.86 | PDPK1 (0.76) | PDPK1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL2142802 | 0.86 | PDPK1 (0.55) | PDPK1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL10256955 | 0.86 | POLB (0.72) | PDPK1POLBKMT2AMEN1MAPT | |
| SCHEMBL657374 | 0.86 | KMT2A (0.72) | PDPK1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL1991487 | 0.84 | PDPK1 (0.55) | PDPK1POLBKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | claimed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | claimed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | claimed |
| US-20260061069-A1 | SIZE-TUNABLE SYNTHETIC PARTICLES FOR IMMUNE CELL ACTIVATION | SLINGSHOT BIOSCIENCES INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12461007-B2 | CD34 stem cell mimics | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12352679-B2 | Synthetic human cell mimic particle for cytometric or coulter device | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250164373-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025090968-A1 | HYDROGEL CELL MIMICS WITH SUBCELLULAR FEATURES | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12282021-B2 | Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy | KINOMICA LIMITED (GB) | 2025-04-22 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258477-A1 | CATALYST AND REACTION PROCESS | Japan Science and Technology Agency (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061069-A1 | SIZE-TUNABLE SYNTHETIC PARTICLES FOR IMMUNE CELL ACTIVATION | ICOS, CD47, CD4 | PDPK1 2983/4885POLB 1843/4885KMT2A 2651/4885 |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | PDPK1 109/4885POLB 4008/4885KMT2A 1777/4885 |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | PDPK1 4324/4885POLB 859/4885KMT2A 2297/4885 |
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | CD4, ICOS, CD69 | PDPK1 3880/4885POLB 3086/4885KMT2A 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.